Transformational Science: Moving from Challenges of High Concentration Protein Formulations Development to Meet the Needs of Highly Potent Bispecifics
Posted on January 9, 2019
Sachin Dubey, PhD, Deputy Director, Formulation, analytical and drug product development
Glenmark Pharmaceuticals
Abstract Bispecifics antibodies by virtue of two different antigen binding regions can bind to two different targets. They are becoming more and more important and many of them are being developed and approved for several clinical indications. One of the advantage of bispecific is their improved pha...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Related Topics and Keywords
formulation analytical, Glenmark, High Concentration Protein Formulations, Highly Potent Bispecifics, Transformational Science
Related Products
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
